Heart rate variability in people with metabolic syndrome

Metabolic syndrome (MS) is characterized by disorders of carbohydrate and fat metabolism, which can lead to the development of cardiac autonomic neuropathy (CAN). Heart rate variability (HRV) analysis is used to assess the state of autonomic regulation. A decrease in HRV indicates unfavourable changes in autonomic regulation and the development of CAN. The purpose of this study was to compare HRV parameters in patients with metabolic syndrome and healthy individuals without signs of MS. We examined 74 patients with metabolic syndrome (mean age 54.4 ± 1.1 years) and 61 healthy subjects (without signs of MS) (mean age 57.0 ± 1.6 years). The results of the study indicate a significant decrease in HRV in people with MS. However, they had significantly lower values of the SDNN index (by 26%), which characterizes the overall power of neurohumoral regulation of heart rate. Differences in the indicators characterizing short-term, vagal influences were especially pronounced: in patients with MS, RMSSD (by 44%) and HF (by 69%) were lower than in controls. The activity of the baroreflex center of the medulla oblongata, assessed by the spectral power of low-frequency waves (LF), was 55% lower in patients with MS compared to controls. There were no significant differences in the mean duration of the R-R interval, the spectral power of very low frequency (VLF) waves, or the ratio of the spectral powers of low and high frequencies (LF/HF, LFn, HFn) in patients with MS compared to controls. No significant shift in the autonomic balance towards sympathicotonia was found in patients with MS. The analysis of variance confirmed the significant effect of the metabolic syndrome factor on HRV. Thus, the data obtained indicate the development of CAN in people with metabolic syndrome, which is an unfavourable prognostic sign. To assess the effect of MS on the rate of aging, the biological age (BA) of the examined people with MS was calculated. The formula for calculating BA was obtained on a group of people without MS. The method of multiple stepwise regression was used. The aging rate was calculated as the difference between biological and chronological age (CA). The average BA in the group of people with MS was 63,20 ± 1,81 years, in the control group – 53.99 ± 1.71 years (p< 0.05). The difference between BA and CA is 8,81 ± 0,94 years in the group of people with MS and -1.01 ± 0.61 in control group (p< 0.05). From this we can conclude that MS can be a factor accelerating aging.